Related Experiment Video
Updated: Jun 13, 2026
04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
Alpha-lipoic acid supplementation: a tool for obesity therapy?
M G Carbonelli1, L Di Renzo, M Bigioni
1Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
Current Pharmaceutical Design
|April 15, 2010
Summary
Alpha-lipoic acid (LA) effectively reduced weight, BMI, and blood pressure in Italian pre-obese and obese individuals. This antioxidant shows promise for treating obesity-related conditions.
Area of Science:
- Biochemistry
- Metabolism
- Nutritional Science
Background:
- Oxidative stress and lipid peroxidation are implicated in cell injury and various diseases.
- Alpha-lipoic acid (LA) and its reduced form (DHLA) are potent antioxidants with potential therapeutic applications.
- LA/DHLA redox couple scavenges reactive oxygen species and recycles other antioxidants.
Purpose of the Study:
- To investigate the efficacy of alpha-lipoic acid (LA) in managing pre-obesity and obesity in Italian adults.
- To assess the impact of LA supplementation on anthropometric measurements and blood pressure.
Main Methods:
- A cohort of 1127 Italian adults (pre-obese and obese) were enrolled.
- Participants received a daily dose of 800 mg of alpha-lipoic acid (LA) for four months.
- Changes in weight, BMI, blood pressure, and abdominal circumference were measured.
Main Results:
- Significant reductions in weight (8-9%), BMI (2-4 points), and blood pressure were observed in both pre-obese and obese groups.
- Substantial decreases in abdominal circumference were noted (females: 6-9 cm; males: 7-11 cm).
- All observed reductions were statistically significant (p<0.001).
Conclusions:
- Alpha-lipoic acid (LA) demonstrates significant beneficial effects in treating pre-obese and obese individuals.
- LA is a promising antioxidant for managing obesity and associated health conditions.
- Further clinical research is warranted to fully elucidate the role and effectiveness of LA therapy.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...